The breakthrough data confirms that Veradermics’ proprietary slow-release technology successfully drives robust hair count increases in women without triggering any of the heart-related side effects associated with traditional oral minoxidil.
What Is It and How Does It Work?
VDPHL01 is an orally administered, extended-release tablet designed to promote scalp hair growth. While it utilizes minoxidil—a well-known drug that encourages hair growth by dilating blood vessels (vasodilation) and flooding hair roots with nutrients—this pill completely re-engineers how the medicine is delivered to the body.
It works through a highly specialized process of Extended-Release Gel Matrix Delivery:
-
Avoiding the “Spike and Crash”: When patients take standard, immediate-release oral minoxidil (which is sometimes used off-label for hair loss), the drug floods the bloodstream all at once. This sharp hormonal spike is what causes dangerous cardiovascular side effects, such as a racing heart rate or sudden drops in blood pressure.
-
The Slow-Release Matrix: VDPHL01 uses a specialized gel-matrix tablet that slowly dissolves inside your system over a full 24 hours.
-
Sustained Growth Signals: By releasing a tiny, continuous stream of the drug, it keeps your hair follicles constantly fed with growth signals while keeping the actual level of the drug in your blood safely below the threshold that triggers heart risks.
The Science: Over 90% Success Rate in Female Pattern Hair Loss
The open-label Phase 2 study (Study 207) evaluated 28 adult female participants suffering from mild-to-moderate pattern hair loss. The women received a low, safe dose of 4.5 mg of VDPHL01 either once or twice daily for six months.
To measure how well the treatment worked, researchers tracked TAHC (Target Area Hair Count) and utilized the AAIRS (Androgenetic Alopecia Impact Rating Scale):
What is TAHC? TAHC stands for Target Area Hair Count. To measure this, investigators mark a tiny, 1-square-centimeter area of the scalp and use high-magnification digital cameras to count the exact number of thick, visible (non-baby) hair strands. A higher TAHC score means the hair is physically multiplying and growing back thicker.
What is the AAIRS? The Androgenetic Alopecia Impact Rating Scale (AAIRS) is a patient-reported outcome scale. It allows study participants to grade their own hair coverage and density improvements, identifying whether their hair looks “improved” or “much improved”.
The clinical results from the six-month study demonstrated highly significant regrowth:
-
Significant Hair Gain: By Month 6, women taking the pill once daily saw an average increase of 22.7 hairs/cm², while those taking it twice daily gained 23.3 hairs/cm² in the target area.
-
High Patient Satisfaction: On the AAIRS scale, 88.9% of the once-daily group and 90.0% of the twice-daily group reported their hair coverage was “improved” or “much improved”.
-
Fast Onset of Action: This steady-release formula worked incredibly fast. Investigators noted visible, measurable hair improvements in 67.2% of patients as early as Month 2.
Read next
Whats the best shampoo for hair loss?
-
A Favorable Safety Record: The study reported zero treatment-related serious adverse events and no heart-related side effects. The most common mild side effects were temporary peripheral edema (mild fluid retention in the ankles/feet) and hypertrichosis (increased non-scalp hair growth).
“We are highly encouraged by the positive results from Study ‘207’ evaluating our proprietary extended-release formulation of VDPHL01 in women with pattern hair loss. Importantly, Study ‘207’ demonstrated strong proof-of-concept ahead of our anticipated Phase 2/3 Study ‘306’ readout.” — Dr. Reid Waldman, CEO of Veradermics.
When Will It Be Available?
-
Current Stage: Veradermics is currently running a large, registration-directed Phase 2/3 trial (Study 306) specifically evaluating the safety and power of VDPHL01 in a larger group of women with pattern hair loss.
-
Timeline: The company expects to announce the final topline results from this larger female study in the first half of 2027. If those results confirm the Phase 2 data, the drug will be submitted for official FDA approval, with expected commercial pharmacy availability around 2028.
How you can benefit from this treatment now
If you are a woman struggling with thinning hair, the positive results of Study 207 offer highly practical steps you can take today:
-
Discuss Safe, Low-Dose Minoxidil with Your Doctor: This study confirms that low, controlled doses of minoxidil are both safe and exceptionally effective for female pattern hair loss. Many specialist dermatologists are already comfortable prescribing low-dose oral minoxidil (LDOM) off-label. You can discuss these new Study 207 results with your doctor to determine if an existing low-dose oral routine is a suitable option for you while you wait for the official, gel-matrix tablet to reach the market.
-
Monitor the Phase 3 Trial Locations: Because Veradermics is actively enrolling female participants for its Study 306 trial, you can search the registry identifier NCT06527365 on ClinicalTrials.gov to see if there is an active clinical trial center near you. Participating in this trial is the only way to gain early access to this “steady-release” gel matrix tablet.
Sources:
-
[cite: 3]
-
[cite: 4]